Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Accumulated Expenses: 2016-2025

Historic Other Accumulated Expenses for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $3.4 million.

  • Rhythm Pharmaceuticals' Other Accumulated Expenses fell 90.73% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 90.73%. This contributed to the annual value of $37.7 million for FY2024, which is 596.93% up from last year.
  • Rhythm Pharmaceuticals' Other Accumulated Expenses amounted to $3.4 million in Q3 2025, which was down 91.51% from $40.0 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Other Accumulated Expenses peaked at $40.0 million during Q2 2025, and registered a low of $229,000 during Q1 2021.
  • For the 3-year period, Rhythm Pharmaceuticals' Other Accumulated Expenses averaged around $16.8 million, with its median value being $5.8 million (2024).
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Other Accumulated Expenses surged by 876.15% in 2024, and later tumbled by 90.73% in 2025.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Other Accumulated Expenses stood at $800,000 in 2021, then soared by 202.38% to $2.4 million in 2022, then soared by 123.65% to $5.4 million in 2023, then skyrocketed by 596.93% to $37.7 million in 2024, then slumped by 90.73% to $3.4 million in 2025.
  • Its Other Accumulated Expenses was $3.4 million in Q3 2025, compared to $40.0 million in Q2 2025 and $38.8 million in Q1 2025.